SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Drug Development
TG Therapeutics Announces Updated Results from the Ongoing Phase II Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS Meeting
October 26, 2017
 · 
6 min read
Drug Development
TG Therapeutics Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS - ACTRIMS Meeting
October 16, 2017
 · 
6 min read
Philips Wins FDA Nod for Small Parts Ultrasound Tr
Drug Development
TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase III Trial
October 16, 2017
 · 
5 min read
Drug Development
TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase III Trial
October 16, 2017
 · 
6 min read
Drug Development
TG Therapeutics Announces Advancement Of Its Anti-PD-L1 Monoclonal Antibody Into Clinical Development
October 5, 2017
 · 
4 min read
Pharm Country
TG Therapeutics Announces TGR-1202 (Umbralisib) Selected For Grant From The National Multiple Sclerosis Society To Support The Development Of TGR-1202 As An Oral B-Cell Targeted Treatment Option In Progressive Multiple Sclerosis (PMS)
September 29, 2017
 · 
6 min read
Drug Development
TG Therapeutics Announces The Phase III ULTIMATE Trials Evaluating TG-1101 In Patients With Multiple Sclerosis Are Now Open For Enrollment
September 15, 2017
 · 
5 min read
Drug Development
TG Therapeutics Announces Successful Outcome From The First Pre-Planned Interim Analysis By Independent DSMB Of The DLBCL Cohort In The UNITY-NHL Phase IIb Trial
August 10, 2017
 · 
4 min read
Business
TG Therapeutics Provides Business Update And Reports Second Quarter 2017 Financial Results
August 9, 2017
 · 
1 min read
Business
TG Therapeutics To Host Conference Call On Second Quarter 2017 Financial Results And Business Update
August 7, 2017
 · 
1 min read
Business
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With The FDA For A Phase III Program Of TG-1101 (Ublituximab) For Patients With Multiple Sclerosis (MS)
August 1, 2017
 · 
6 min read
Drug Development
TG Therapeutics Recaps Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The 3rd Congress Of The European Academy Of Neurology
June 26, 2017
 · 
4 min read
Drug Development
TG Therapeutics Recaps Data From Triple Combination Therapy Trials At The 22nd European Hematology Association Annual Congress
June 26, 2017
 · 
6 min read
Drug Development
TG Therapeutics Recaps Positive Data From The Phase III GENUINE Trial And Data From The Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 14th International Conference On Malignant Lymphoma
June 16, 2017
 · 
11 min read
Drug Development
TG Therapeutics Announces Follow-Up Data For Combination Of TGR-1202 (Umbralisib) Plus Ibrutinib In Patients With Relapsed Or Refractory CLL And MCL At The 14th International Conference On Malignant Lymphoma
June 14, 2017
 · 
6 min read
Drug Development
TG Therapeutics Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO
June 5, 2017
 · 
8 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS